What is EmCyte?
Headquartered in Fort Myers, Florida, EmCyte Corporation is a global frontrunner in platelet-rich plasma (PRP) and progenitor stem cell biologics. The company's PURE regenerative product solutions are recognized for setting new industry standards through versatile protocols and exceptional recovery outcomes. EmCyte operates a 30,000-square-foot manufacturing facility featuring certified clean rooms and advanced equipment, reflecting its commitment to quality and innovation. With over two decades of experience, EmCyte's contributions have made a tangible clinical difference worldwide, supported by a team of experts providing advanced training and clinical support.
How much funding has EmCyte raised?
EmCyte has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in EmCyte
PPP
Public-Private Partnership
What's next for EmCyte?
The substantial late-stage funding and recent strategic investment signal EmCyte's readiness for accelerated growth and market expansion. This capital infusion is likely to fuel further research and development, enhance manufacturing capabilities, and broaden the global reach of its regenerative product solutions. The company's focus on innovation and clinical impact positions it for continued leadership in the rapidly evolving field of regenerative medicine, potentially leading to new therapeutic applications and market penetration.
See full EmCyte company page
